Mechanisms of DNA damage-induced, p53-dependent repression of the Cdc25C Phosphat
Mechanisms of DNA damage-induced, p53-dependent repression of the Cdc25C Phosphat
批准号:
8537529
负责人:
Luis A. Carvajal
金额:
$3.71万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-11-16 至 2012-06-19
关键词:
AddressApoptosisBerylliumBindingBinding SitesBoxingCancer PatientCdc25C proteinCell CycleCell Cycle CheckpointCell Cycle ProgressionCell DeathCellsCellular StressConsensusCyclin-Dependent KinasesDNADNA BindingDNA DamageDNA MethyltransferaseDNA Modification MethylasesDNA Repair PathwayDependenceDown-RegulationDoxorubicinElementsG2/M TransitionGC Rich SequenceGene TargetingGenesGenetic TranscriptionGenomeHistonesHumanHypoxiaIndiumLeadMalignant NeoplasmsMammalian CellMediatingMethodsMolecularMolecular AnalysisMolecular TargetMutateOncogene ActivationPharmaceutical PreparationsPhosphoric Monoester HydrolasesPhysiologicalPlayProtein FamilyProtein p53Relative (related person)RepressionResponse ElementsRoleSystemTranscriptional ActivationTumor Suppressor Proteinsbasecancer cellgene repressionneoplastic cellnovel therapeutic interventiononcoprotein p21overexpressionpromoterpublic health relevanceresponsesenescencetherapeutic targettooltranscription factortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The tumor suppressor p53 is the most commonly mutated gene found in human cancers [3]. It plays a vital role in guarding mammalian cells against tumorigenesis [22,23]. The Cdc25C phosphatase plays an important role in cell cycle progression at the G2/M transition [7-10]. Its activity is inhibited in response to DNA damage thereby contributing to the G2 checkpoint response [7-10]. Cdc25C is a target for transcriptional repression by p53. Overexpression of Cdc25C sensitizes cancer cells to DNA damage induced cell death [11, 12]. Interestingly, normal untransformed cells are not sensitized to this treatment [12]. Therefore, Cdc25C repression inhibition could lead to a novel therapeutic approach in combination with DNA damage. In order to address this possibility, a clear molecular basis for p53-dependent repression of Cdc25C must be described. As of yet, three distinct mechanisms of repression have been proposed, one involving direct binding to DNA by p53 and two indirect involving different elements. Each of which may provide molecular targets for inhibition. The present study aims to dissect the molecular basis for p53-dependent repression of Cdc25C and to explore its relevance as a tool that can be exploited in order to enhance chemotherapeutic responses in cancer patients. Hypothesis: It is hypothesized that the p53 response element is required in order for p53 to bind to the Cdc25C promoter and for the recruitment of co-repressors. Additional factors, such as p21, may be required for this repression. Furthermore, inhibition of this mechanism in cancer cells can abrogate DNA damage-induced Cdc25C repression, which results in heightened sensitivity to DNA damage-induced cell death. Specific Aims: Aim 1: Analysis of the molecular basis for DNA damage-induced p53-dependent repression of Cdc25C. A) Characterize the role of Histone Deacetylases (HDACs) and DNA methyltransferases (DNMTs) in Cdc25C repression. B) Study the role of CCAAT box binding factor, NF-Y in p53-dependent repression of Cdc25C. Aim 2: Functional analysis of different elements in the Cdc25C promoter. A) Characterize relevant elements in the Cdc25C promoter in order to identify potential therapeutic targets. B) Explore methods to use Cdc25C repression inhibition as a novel therapeutic approach. Aim 3: Study of the role of p21 in the p53-induced repression of Cdc25C. A) Investigate the p21 dependence of p53 and co-repressor recruitment to the Cdc25C promoter. B) Study the role of Rb family proteins in Cdc25C mediated repression in response to DNA damage.
PUBLIC HEALTH RELEVANCE: The present study aims to dissect the molecular basis for p53-dependent repression of Cdc25C and to explore its relevance as a tool that can be exploited in order to enhance chemotherapeutic responses in cancer patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of DNA damage-induced, p53-dependent repression of the Cdc25C Phosphat
-
批准号:7914522
-
项目类别:
-
资助金额:$3.34万
-
财政年份:2010
-
负责人:Luis A. Carvajal
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: